This Visualizing Health Policy infographic, produced in partnership with the Journal of the American Medical Association (JAMA), provides a snapshot of Medicare and end-of-life care.
- view as grid
- view as list
This Visualizing Health Policy infographic, produced in partnership with the Journal of the American Medical Association (JAMA), provides a snapshot of Medicare and end-of-life care
Web Event: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs
On Wednesday, October 5, from noon to 1 p.m. ET, the Kaiser Family Foundation will host a web conversation to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted.
As policymakers in Washington scrutinize the rising cost of the EpiPen auto-injector, a new analysis from the Kaiser Family Foundation shows that Medicare Part D spending for the potentially life-saving device increased by more than 1000 percent between 2007, the year after the Part D drug benefit took effect, and…
This data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).
This issue brief provides a landscape of the status of U.S. funding for Zika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects. The brief compares the Congressionally approved Zika funding levels, which provides $1.1 billion to the Zika response, to the President’s February 22nd request, the House and Senate bills that passed each chamber in May, and a Conference Agreement that had been approved by the House in June, but was blocked in the Senate and opposed by the Administration.
Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs
On Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in coming years.
Zika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects, has recently become a global challenge, and with the first cases of local transmission now reported in the U.S., a domestic one as well. No new funding for Zika has yet been appropriated…
This brief provides an overview of the implementing organizations that received U.S. global health funding from the U.S. Agency for International Development (USAID) in FY 2015.
This issue brief examines the latest facts about Medicare spending and financing, includes the most recent historical and projected Medicare spending data from the Centers for Medicare and Medicaid Services (CMS) Office of the Actuary (OACT), the 2016 annual report of the Boards of Medicare Trustees, and the 2016 Medicare baseline and projections from the Congressional Budget Office (CBO). It discusses historical and projected spending trends, program financing, Medicare’s financial condition, the Independent Payment Advisory Board (IPAB), and the future outlook.